Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2007 1
2008 2
2010 4
2011 5
2012 6
2013 5
2014 2
2015 2
2016 4
2017 6
2018 4
2019 6
2020 7
2021 2
2022 3
2023 2
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Pioglitazone and bladder cancer: FDA's assessment.
Hampp C, Pippins J. Hampp C, et al. Pharmacoepidemiol Drug Saf. 2017 Feb;26(2):117-118. doi: 10.1002/pds.4154. Epub 2017 Jan 9. Pharmacoepidemiol Drug Saf. 2017. PMID: 28067434 Review. No abstract available.
Teratogenic Risk Impact Mitigation (TRIM): Development of Explicit Criteria to Facilitate Decisions Regarding Teratogenic Risk Mitigation Strategies.
Ewig CLY, Wang Y, Smolinski NE, Toyserkani GA, LaCivita C, Lackey L, Eggers S, Sahin L, Abu-Rustum RS, Bateman BT, Berard A, Chambers CD, Choby B, Conover EA, Greene MF, Hernández-Díaz S, Jamieson DJ, Običan SG, Polifka JE, Roussos-Ross K, Sheffield JS, Lavigne SV, Zimmermann EM, Laffan SB, DeLise AM, Gilsenan AW, Hammad TA, Hampp C, Hardy JR, Knox CA, Shields K, Smith MY, Sobel RE, Tassinari MS, Maro JC, Rasmussen SA, Winterstein AG. Ewig CLY, et al. Among authors: hampp c. Drug Saf. 2025 Dec;48(12):1387-1397. doi: 10.1007/s40264-025-01581-2. Epub 2025 Aug 5. Drug Saf. 2025. PMID: 40762949 Free PMC article.
Ranking the Importance of Prognostic Factors for Relapsed/Refractory Multiple Myeloma: International Physician Panel Consensus Following a Systematic Literature Review.
Kumar S, Leleu X, Weisel KC, Popat R, Suero B, Craigie S, Spin P, Patel L, Ramirez AO, Hampp C, Ge W, Ma Q, Jagannath S. Kumar S, et al. Among authors: hampp c. Clin Lymphoma Myeloma Leuk. 2025 Oct;25(10):730-738.e11. doi: 10.1016/j.clml.2025.03.013. Epub 2025 Apr 3. Clin Lymphoma Myeloma Leuk. 2025. PMID: 40410023 Free article.
Prognostic Factors and Effect Modifiers in Patients With Relapse or Refractory Diffuse Large B-Cell Lymphoma After Two Lines of Therapy: A Systematic Literature and Expert Clinical Review.
von Tresckow B, Abrisqueta P, Zamanillo I, Pareja ÁS, Kuang Y, Uyei J, Shah M, Walsh L, Thorley E, Cantos K, Rashidi E, Hampp C, Jalbert JJ, Archambault AN, Xu Y, Aggarwal S, Ambati S, Mohamed H, Ma Q, Jiménez-Ubieto A. von Tresckow B, et al. Among authors: hampp c. Eur J Haematol. 2025 Aug;115(2):104-116. doi: 10.1111/ejh.14423. Epub 2025 May 9. Eur J Haematol. 2025. PMID: 40344463 Free PMC article.
Longitudinal study of optic cup progression in children.
Park HJ, Hampp C, Demer JL. Park HJ, et al. Among authors: hampp c. J Pediatr Ophthalmol Strabismus. 2011 May-Jun;48(3):151-6. doi: 10.3928/01913913-20100719-06. Epub 2010 Jul 22. J Pediatr Ophthalmol Strabismus. 2011. PMID: 20669878
56 results